All In Biotech

Drug Trial Radar · NCT02850406

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

147

Actual

Start

Jul 5, 2016

Primary completion

Oct 2, 2023

Study completion Oct 2, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of four parts, Parts A, B, C, and D. * Part A is a single dose pharmacokinetic (PK) study in pediatric participants with Sickle Cell Disease ages 6 to 17 years. * Part B is a multiple dose, safety, exploratory, efficacy, and PK study in adolescent participants with Sickle Cell Disease ages 12 to 17 years. * Part C is a multiple dose, safety, tolerability, and PK study, which includes the assessment of hematological effects and the effect on TCD flow velocity of voxelotor in pediatric participants with Sickle Cell Disease ages 4 to 17 years. * Part D is a multiple dose, safety, tolerability, and PK study, which examines the hematological effects of voxelotor in pediatric participants with Sickle Cell Disease ages 6 months to \< 4 years.

Conditions

  • Sickle Cell Disease

Interventions

  • VoxelotorDrug

    * Part A: Voxelotor will be administered as oral capsules or tablets * Part B: Voxelotor will be administered as oral capsules or tablets * Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension * Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Concentration (Cmax) of Voxelotor in Whole BloodTime frame: pre-dose, 2, 8, 24, 48, 96, 168 and 336 hours post-dose
  2. Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Voxelotor in Whole BloodTime frame: pre-dose, 2, 8, 24, 48, 96, 168 and 336 hours post-dose
  3. Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 Extrapolated to Infinity (AUC0-inf) of Voxelotor in Whole BloodTime frame: pre-dose, 2, 8, 24, 48, 96,168 and 336 hours post-dose
  4. Part B: Change From Baseline to Week 24 in Hemoglobin LevelTime frame: Baseline, Week 24
  5. Part C: Change From Baseline to Week 48 in Cerebral Blood FlowTime frame: Baseline, Week 48
  6. Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From start of study treatment up to 28 days after study treatment discontinuation (Up to 52 weeks)

Locations

20 sites in 3 countries. Site status is shown where the registry gives one.

  • Brentwood Clinic UCSF Benioff Children's Hospital Oakland

    Brentwood, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta Scottish Rite

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Illinois at Chicago Clinical Research Center

    Chicago, Illinois

  • Our Lady of the Lake Children's Hospital (IP Address)

    Baton Rouge, Louisiana

  • Children's Mercy Hospital

    Kansas City, Missouri

  • Rutgers-Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina

  • University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital

    Cleveland, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • American University of Beirut - Medical Center

    Beirut, Lebanon

  • Rafik Hariri University Hospital

    Beirut, Lebanon

  • Nini Hospital

    Tripoli, Lebanon

  • Barts Health NHS Trust, The Royal London Hospital

    London, United Kingdom

  • Guy's and St Thoma's NHS Foundation Trust, Evelina London Children's Hospital

    London, United Kingdom

  • Manchester University NHS Foundation Trust, Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • University College London Hospital, NHS Foundation Trust

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.